ILA
$111M19mo
Island Pharmaceuticals
Biotechnology · Infectious disease
Developing ISLA-101 (fenretinide) as a broad-spectrum antiviral, initially targeting dengue. Phase 2 human challenge study completed.
Cash data from Dec 2025 4CFigures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$6.9M
Dec 2025 4C
Runway
19moSTABLE
Based on Dec 2025 4C
Market Cap
$111M
Burn Rate
$1.1M/qtr
Dec 2025 4C
Shares Outstanding
296M
Pipeline Assets
1
Latest Insight(1)
8 Mar 2026PartnershipAntiviral pipeline expansion through strategic collaboration
Burnet Institute·co development
3M Price
ILA.ASX$0.375-12.8% 3M
Low $0.350High $0.490
Pipeline Assets (1)
ISLA-101 (fenretinide)Dengue
Phase 2Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
ISLA-101 (fenretinide)
Dengue
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Competitive Landscape
16 competitor trialsPhase 2+ · Non-ASX
Dengue16 active trials
1 Ph46 Ph32 Ph2/37 Ph2
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
3 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
Int J Pharm2026-04· fenretinide
Oncogene2026-04· fenretinide
Antiviral Res2026-03· fenretinide
Catalysts (7)· 3 upcoming · 4 past
ISLA-101 Phase 2b therapeutic cohort full data package
UpcomingExpectedarrow_upwardHigh30 June 2026
ISLA-101 end of Phase 2 meeting with FDA
UpcomingExpectedarrow_upwardHigh30 Sept 2026
ISLA-101 strategic partnership / licensing deal
UpcomingSpeculativearrow_upwardHigh31 Dec 2026
expand_more4 past catalysts
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Delivery Consistency Index
Delivery
–Insufficient data
0/3 data points needed
Timeline adherence · phase-adjusted tolerance · recency-weighted · min 3 catalysts
Capital discipline
–Insufficient data
1/2 data points needed
Burn rate stability · stage-adjusted thresholds · runway trend · R&D focus
Outcome quality (positive/negative readouts) reflects the science, not execution — shown above but excluded from the score.
These metrics reflect historical operational data only. They are not predictive of future performance, do not constitute investment advice, and should not be used as the basis for any investment decision.
⚠ TIMELINE CHANGESCT.GOV · AUTO-DETECTED
These changes were automatically detected by comparing ClinicalTrials.gov records over time. A slipped date means the trial's expected completion moved later; pulled forward means it moved earlier.
Clinical Trials(5)
No active trials
Announcements(5)
handshake
PartnershipPSauto_awesome
Antiviral pipeline expansion through strategic collaboration8 Mar 2026
expand_more151KB